Home > Publications Database > SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies. > print

001     278782
005     20250604100729.0
024 7 _ |a 10.1002/alz.14307
|2 doi
024 7 _ |a pmid:39985404
|2 pmid
024 7 _ |a pmc:PMC12079645
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2025-00618
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kuhn, Elizabeth
|0 P:(DE-2719)9002169
|b 0
|e First author
245 _ _ |a SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1748937983_11720
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Specific features of subjective cognitive decline (SCD-plus) have been proposed to indicate an increased risk of preclinical Alzheimer's disease (AD). However, few studies have examined how these features relate to AD biomarkers in cognitively unimpaired (CU) older adults.Meta-analyses were performed using cross-sectional data from nine cohorts (n = 7219, mean age (SD): 71.17 (5.9), 56.5% female) to determine associations of SCD-plus features with positron emission tomography (PET)- or cerebrospinal fluid (CSF)-derived amyloid beta (Aβ) and tau biomarkers.Participants with preclinical AD (community-based only) were more likely to fulfill SCD-plus features. The presence of self-reported memory decline, associated concern/worry, and a higher number of fulfilled features were all associated with high Aβ levels. Only the latter was associated with abnormal tau.Simultaneous endorsement of multiple SCD-plus features is a robust indicator of abnormal AD biomarkers in CU older adults, whereas isolated SCD features seem only sensitive to elevated Aβ, supporting their value as early behavioral markers of preclinical AD.About two-tenths of our sample had abnormal amyloid beta (Aβ) levels with evidence of subjective cognitive decline (SCD). Preclinical AD subsamples (community-based) had a higher percentage of participants meeting SCD-plus features. Self-reported memory decline and concern/worry were the sole features associated with high Aβ, but not tau, burden. A higher number of fulfilled SCD-plus features are linked to high Aβ and tau burden. Use of multiple SCD-plus features may help identify early stages of biological AD.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a SCD‐Initiative
|2 Other
650 _ 7 |a amyloid pathology
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a meta‐analysis
|2 Other
650 _ 7 |a positron emission tomography
|2 Other
650 _ 7 |a subjective cognitive decline
|2 Other
650 _ 7 |a tau burden
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnosis
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Klinger, Hannah M
|0 0009-0006-5633-2954
|b 1
700 1 _ |a Amariglio, Rebecca E
|b 2
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 3
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 4
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 5
|u dzne
700 1 _ |a Heneka, Michael T
|0 P:(DE-2719)2000008
|b 6
700 1 _ |a Chételat, Gael
|0 0000-0002-4889-7932
|b 7
700 1 _ |a Rentz, Dorene M
|b 8
700 1 _ |a Sperling, Reisa A
|b 9
700 1 _ |a Ebenau, Jarith L
|b 10
700 1 _ |a Butterbrod, Elke
|b 11
700 1 _ |a Van Der Flier, Wiesje M
|0 0000-0001-8766-6224
|b 12
700 1 _ |a Sikkes, Sietske A M
|b 13
700 1 _ |a Teunnissen, Charlotte E
|0 0000-0002-4061-0837
|b 14
700 1 _ |a Van Harten, Argonde C
|0 0000-0002-1477-8724
|b 15
700 1 _ |a Van De Giessen, Elsmarieke M
|0 0000-0001-9956-4233
|b 16
700 1 _ |a Rami, Lorena
|0 0000-0002-7411-1921
|b 17
700 1 _ |a Tort, Adria
|0 0000-0002-5646-0482
|b 18
700 1 _ |a Sánchez Benavides, Gonzalo
|0 0000-0003-3454-800X
|b 19
700 1 _ |a Gifford, Katherine A
|0 0000-0001-6232-9408
|b 20
700 1 _ |a Van Hulle, Carol
|b 21
700 1 _ |a Buckley, Rachel F
|0 0000-0002-5356-5537
|b 22
700 1 _ |a Initiative, Alzheimer's Disease Neuroimaging
|b 23
|e Collaboration Author
700 1 _ |a Biomarkers, Australian Imaging
|b 24
700 1 _ |a Lifestyle flagship study of ageing, A4 Study Team
|b 25
|e Collaboration Author
700 1 _ |a Study, DELCODE
|b 26
|e Collaboration Author
700 1 _ |a Study, Harvard Aging Brain
|b 27
|e Collaboration Author
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 28
|e Contributor
|u dzne
700 1 _ |a Bürger, Katharina
|0 P:(DE-2719)2811351
|b 29
|e Contributor
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 30
|e Contributor
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 31
|e Contributor
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 32
|e Contributor
|u dzne
700 1 _ |a Priller, Joseph
|b 33
|e Contributor
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 34
|e Contributor
|u dzne
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 35
|e Contributor
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 36
|e Contributor
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 37
|e Contributor
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 38
|e Contributor
|u dzne
773 _ _ |a 10.1002/alz.14307
|g Vol. 21, no. 5, p. e14307
|0 PERI:(DE-600)2201940-6
|n 5
|p e14307
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.docx
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP3.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/278782/files/DZNE-2025-00618.pdf
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.doc
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.odt
856 4 _ |u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP2.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/278782/files/DZNE-2025-00618%20SUP3.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/278782/files/DZNE-2025-00618.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:278782
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002169
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2000005
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 28
|6 P:(DE-2719)2810593
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 29
|6 P:(DE-2719)2811351
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 30
|6 P:(DE-2719)2000055
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 31
|6 P:(DE-2719)2812234
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 32
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 34
|6 P:(DE-2719)2812825
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 35
|6 P:(DE-2719)2812035
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 36
|6 P:(DE-2719)2811324
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 37
|6 P:(DE-2719)2000026
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 38
|6 P:(DE-2719)2811317
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 0
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 1
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)5000006
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21